Trial Profile
A one arm, open label, multi-center phase II study to evaluate the safety and efficacy of IVIG [GCAN 101] in the treatment of various metastatic solid tumors for which there is no better alternative treatment
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 03 Nov 2021
Price :
$35
*
At a glance
- Drugs GCAN 101 (Primary)
- Indications Colorectal cancer; Malignant melanoma; Prostate cancer
- Focus Therapeutic Use
- 21 Sep 2006 Status change
- 22 Nov 2005 New trial record.